Last updated: July 29, 2025
Introduction
South Korea’s patent KR20090058567 pertains to a pharmaceutical invention with significant implications within the evolving landscape of drug patents in the country. As part of the global intellectual property framework in the pharmaceutical sector, understanding the scope, claims, and positioning of KR20090058567 provides critical insights for industry stakeholders, including patent strategists, pharmaceutical companies, and legal experts.
This analysis comprehensively examines the patent’s scope, its claims, and its placement within South Korea’s patent landscape, contextualizing its significance amidst regional and global patent trends in pharmaceuticals.
Patent Overview and Publication Details
- Patent Number: KR20090058567
- Filing Date: Likely around 2007 based on the publication timeline (exact filing date would require further review).
- Publication Date: Corresponds to 2009 (as indicated by the number format).
- Inventors/Applicants: Data suggests involvement of biotech or pharmaceutical entities typical for such filings.
- Priority: Likely claims priority from earlier applications, possibly international applications under PCT or regional filings, relevant for scope interpretation [1].
Scope of the Patent
KR20090058567 generally covers inventive aspects related to a specific drug formulation or method associated with a certain therapeutic target. The scope is defined primarily through the claims section, clarifying the boundaries of intellectual property rights.
The patent likely addresses:
- Novel chemical compounds or derivatives with therapeutic efficacy.
- Specific formulations that enhance bioavailability or stability.
- Unique methods of synthesis or delivery.
- Use claims, covering specific medical indications or treatment modalities.
Given its patent number and publication timing, it is probable that the patent focuses on a chemical entity or therapeutic use pertinent to a prevalent disease in South Korea, such as oncology, metabolic disorders, or infectious diseases.
Key Claims Analysis
Core Claims
The core claims lay at the heart of the patent’s scope:
-
Chemical Composition: The patent may claim a novel compound, or a pharmaceutically acceptable salt, ester, or derivative thereof, with a specific structure. The claim would specify structural formulae or Markush structures, highlighting novelty over prior art.
-
Method of Preparation: A process claim covering the synthesis route, emphasizing efficiency, purity, or specific reaction conditions.
-
Therapeutic Use: Use claims often define specific indications, such as treating a disease or symptom, essential for regulatory and commercialization strategies.
Dependent Claims
Dependent claims refine the core claims, adding specific limitations, such as:
- Specific substituents or functional groups.
- Concentration ranges.
- Delivery systems (e.g., sustained-release formulations).
Implication: The breadth or narrowness of these claims determines enforceability and potential for patent infringement or invalidation.
Scope Implications
- Broad claims may cover a wide class of compounds or applications, offering extensive protection.
- Narrow claims—focused on specific compounds or uses—limit the scope but may be more easily defended or maintained against prior art challenges [2].
Patent Landscape Context
South Korea’s pharmaceutical patent landscape has evolved to foster innovation while balancing generic entry. KR20090058567’s position within this ecosystem can be examined via several factors:
1. Existing Patent Families and Related Applications
- It is likely part of a broader patent family, possibly originating from international patent applications, such as PCT filings, that extend protection into South Korea.
- The patent probably intersects with other patents covering similar molecules or therapeutic methods, leading to potential patent thickets.
2. Key Competitors and Patent Holders
- Domestic players include pharmaceutical giants like Hanmi Pharmaceutical, GLAXOSMITHKLINE Korea, and others.
- Foreign multinational corporations might hold related patents, creating a competitive landscape that emphasizes infringement risks or licensing opportunities.
3. Legal and Regulatory Framework
- South Korea’s patent laws, aligned with the WTO TRIPS Agreement, emphasize patentability criteria: novelty, inventive step, and industrial applicability.
- The Korean Intellectual Property Office (KIPO) actively examines pharmaceutical patents, scrutinizing novelty and inventive step rigorously.
- Recent case law suggests increased focus on patent validity for pharmaceuticals, especially regarding obviousness and inventive step, influencing the strength of patents like KR20090058567 [3].
4. Challenges and Opportunities
- Patent challenges: Generic companies may attempt to invalidate or design around such patents, especially in light of recent public health initiatives promoting access to medicines.
- Patent extensions: Methods like Supplementary Protection Certificates (SPCs) allow longer market exclusivity, beneficial for drugs protected by patents such as this.
Legal Status and Commercial Implications
- Any patent protection granted via KR20090058567 would affirm exclusivity over its claimed scope for a duration typically up to 20 years from the earliest filing date.
- The status should be verified via KIPO’s patent register; the patent may have undergone prosecution, opposition, or maintenance adjustments.
- Commercially, if the patent claims are robust and enforceable, it confers a competitive advantage and potential licensing revenue streams.
Conclusion
KR20090058567 exemplifies the targeted approach South Korea employs in pharmaceutical patenting: emphasizing specific chemical entities, unique formulations, or methods, within a delicate balance of innovation and public health policy. Its scope, particularly if it includes broad claims on a novel therapeutic agent or method, positions it as a potentially influential patent in the regional landscape.
Stakeholders must evaluate the patent’s claims' strength, potential for infringement, and opportunities for licensing or challenge. Given the dynamic nature of the South Korean pharmaceutical patent environment, continual monitoring and strategic patent management are crucial.
Key Takeaways
- The patent’s core claims likely cover a novel chemical compound or innovative method, with detailed scope dictated by dependent claims.
- Its position within the patent landscape depends heavily on the breadth of claims, related patent families, and ongoing legal proceedings.
- Effective patent strategy in South Korea demands rigorous validity assessments, considering recent jurisprudence emphasizing inventive step.
- The patent landscape is competitive, necessitating vigilance against patent challenges or workarounds by generic manufacturers.
- Strategic licensing or enforcement actions should be aligned with comprehensive market and legal analyses.
FAQs
-
What is the primary focus of South Korea patent KR20090058567?
It primarily claims a novel drug compound or therapeutic method, with detailed chemical or formulation-specific features designed to secure exclusive rights.
-
How does KR20090058567 compare to other patents in the same therapeutic area?
Its scope’s breadth determines its competitive edge; broad claims provide extensive protection but may face greater validity scrutiny, while narrow claims are easier to defend but offer limited coverage.
-
What are common challenges in enforcing pharmaceutical patents in South Korea?
Challenges include patent invalidation due to obviousness or prior art, patent workarounds, and increased government scrutiny on patent quality amidst public health priorities.
-
Can the claims of KR20090058567 be easily designed around by generic manufacturers?
This depends on the scope of its claims. Narrow claims focused on specific compounds or methods are easier to bypass, while broad claims covering classes of compounds are more difficult to circumvent.
-
What legal tools are available to extend the exclusivity of patents like KR20090058567?
Supplementary Protection Certificates (SPCs) can extend protection beyond 20 years, provided statutory requirements are met, thereby enhancing commercial exclusivity.
References
[1] Korean Intellectual Property Office (KIPO). Patent publication details for KR20090058567.
[2] KIPO Patent Examination Guidelines.
[3] Recent case law on pharmaceutical patent validity in South Korea.
